Genentech Tallies Another Quarter Of Strong Earnings

Like a broken record playing a song investors never tire of hearing, Genentech Inc. chalked up another satisfying quarter, with Avastin and Herceptin sales benefiting from a parade of positive news this spring. (BioWorld Today)